Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Facing Pricing Pressure And Generic Erosion, Simcere Shifts To Innovative Products For Future Growth: China Earnings Roundup (Part I)

This article was originally published in PharmAsia News

Executive Summary

China’s healthcare industry saw slower growth in the third quarter. In a recurring feature, PharmAsia News combs through earnings reports to bring you highlights of China’s leading pharma companies and how their efforts affect different sectors of the industry.

Advertisement

Related Content

Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity
Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal
Under Industry Pressure, China Blinks On Restricting Use Of Anti-infectives - Or Does It?
With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
Simcere Will Co-Develop Cancer Drugs With BMS; A New R&D Model Between China And U.S.?
China Releases New Regs To Step Up Quality Control For Essential Drugs; Second Part Of EDL Expected In November

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC076776

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel